Figure 4

![Figure 4: Molecular targets of CAM therapies in the Th17 signaling cascade, including effects on STAT3 phosphorylation, RORgamma-t expression, and downstream IL-17 secretion.]()

> Source: Aristo Vojdani et al. "The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II.." *Evidence-based complementary and alternative medicine : eCAM*, 2011. PMID: [19622601](https://pubmed.ncbi.nlm.nih.gov/19622601/)

<figure>
  <img src="" alt="Molecular targets of CAM therapies in the Th17 signaling cascade, including effects on STAT3 phosphorylation, RORgamma-t expression, and downstream IL-17 secretion." />
  <figcaption>Figure 4. Molecular targets of CAM therapies in the Th17 signaling cascade, including effects on STAT3 phosphorylation, RORgamma-t expression, and downstream IL-17 secretion.<br>  Source: Aristo Vojdani et al. "The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part II.." <em>Evidence-based complementary and alternative medicine : eCAM</em>, 2011. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/19622601/">19622601</a></figcaption>
</figure>